Solventum (NYSE:SOLV) Earns Sell Rating from Analysts at Rothschild & Co Redburn

Rothschild & Co Redburn began coverage on shares of Solventum (NYSE:SOLV) in a research report report published on Tuesday, Marketbeat reports. The firm issued a sell rating and a $60.00 price target on the stock.

Several other equities analysts also recently weighed in on SOLV. Weiss Ratings reiterated a “hold (c)” rating on shares of Solventum in a report on Tuesday, January 27th. Piper Sandler reaffirmed an “overweight” rating on shares of Solventum in a report on Wednesday, December 17th. Wall Street Zen lowered shares of Solventum from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. Zacks Research cut shares of Solventum from a “strong-buy” rating to a “hold” rating in a report on Monday, December 1st. Finally, Wells Fargo & Company upgraded shares of Solventum to a “hold” rating in a research report on Wednesday, March 18th. Seven analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $90.64.

Solventum Stock Performance

Shares of SOLV opened at $64.69 on Tuesday. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.89 and a current ratio of 1.23. The stock has a 50-day moving average of $73.38 and a two-hundred day moving average of $75.56. The stock has a market cap of $11.22 billion, a P/E ratio of 7.29, a P/E/G ratio of 1.06 and a beta of 0.40. Solventum has a one year low of $60.70 and a one year high of $88.20.

Solventum (NYSE:SOLV) last announced its quarterly earnings data on Thursday, February 26th. The company reported $1.57 earnings per share for the quarter, beating analysts’ consensus estimates of $1.50 by $0.07. Solventum had a return on equity of 25.26% and a net margin of 18.69%.The business had revenue of $2 billion for the quarter, compared to analyst estimates of $1.96 billion. During the same period in the prior year, the company earned $1.41 earnings per share. The company’s revenue was down 3.7% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. As a group, research analysts predict that Solventum will post 6.58 EPS for the current year.

Insider Activity at Solventum

In other Solventum news, Director Amy Mcbride Wendell bought 1,475 shares of the firm’s stock in a transaction dated Tuesday, March 10th. The shares were purchased at an average price of $68.03 per share, for a total transaction of $100,344.25. Following the transaction, the director directly owned 5,039 shares of the company’s stock, valued at approximately $342,803.17. This represents a 41.39% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.05% of the stock is owned by company insiders.

Institutional Trading of Solventum

Institutional investors have recently modified their holdings of the stock. Assetmark Inc. boosted its holdings in Solventum by 21.4% during the 4th quarter. Assetmark Inc. now owns 725 shares of the company’s stock valued at $57,000 after acquiring an additional 128 shares during the period. Allworth Financial LP boosted its stake in shares of Solventum by 2.8% in the third quarter. Allworth Financial LP now owns 4,788 shares of the company’s stock valued at $350,000 after purchasing an additional 129 shares during the period. Hilltop National Bank boosted its stake in shares of Solventum by 71.3% in the fourth quarter. Hilltop National Bank now owns 310 shares of the company’s stock valued at $25,000 after purchasing an additional 129 shares during the period. CIBC Private Wealth Group LLC grew its holdings in shares of Solventum by 0.5% in the third quarter. CIBC Private Wealth Group LLC now owns 24,710 shares of the company’s stock valued at $1,804,000 after purchasing an additional 134 shares in the last quarter. Finally, BOKF NA lifted its holdings in Solventum by 6.9% during the 3rd quarter. BOKF NA now owns 2,193 shares of the company’s stock worth $160,000 after buying an additional 141 shares in the last quarter.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.